October 2, 2024 From Words to Action: Ensuring True Accessibility at Scientific Conferences I want to talk about access and inclusion at scientific conferences and putting actions to words or values. Conferences are...
October 1, 2024 The AMR Accelerator Calls to Action: European Capacity for Antibiotic R&D Requires Long-term Funding Note: You are reading this information because Critical Path Institute is a partner of both ERA4TB and Unite4TB.
September 12, 2024 C-Path’s Inaugural Global Impact Conference Charts the Future of Drug Development C-Path successfully concluded its inaugural Global Impact Conference (CGIC) on September 11, 2024.
September 5, 2024 Cystic Fibrosis Therapeutics Development Network Contributes New Data Sets to C-Path’s RDCA-DAP, Advancing CF Research and Treatment Strategies Critical Path Institute (C-Path) today announced the addition of significant new data sets...
August 22, 2024 C-Path’s TRxA Announces $250,000 Grant for Drug Development Project in Prostate Cancer C-Path proudly announced today a $250,000 grant award to Peter Wipf, Ph.D...
August 20, 2024 C-Path Receives Data Transfer from The Champ Foundation Registry C-Path has received its first data transfer of natural history data on single large-scale mitochondrial DNA...
August 20, 2024 C-Path’s RDCA-DAP Announces Strategic Partnership with Vivli to Enhance Clinical Trials Data Sharing for Rare Diseases C-Path today announced a strategic data sharing partnership with Vivli, the nonprofit...
August 13, 2024 C-Path’s TRxA Announces $250,000 Grant for Drug Development Project on Antibiotic-Resistant Gram-Negative Bacteria TUCSON, Ariz. August 13, 2024– Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) announced toda
August 12, 2024 C-Path Welcomes CuraSen As Newest CPP Member C-Path is thrilled to welcome CuraSen Therapeutics as the newest member of its Critical Path for Parkinson’s Consortium.
August 8, 2024 C-Path’s TRxA Announces $250,000 Award for Drug Development Project in ALS TUCSON, Ariz., August 8, 2024 – Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) announced tod
